Geoffrey Kim, a former official at the US Food and Drug Administration, has joined AstraZeneca Plc as head of oncology strategic combinations. A medical doctor and oncologist, Dr Kim was most recently director of oncology products in the Office of Haematology Oncology Products at the FDA. Dr Kim received his medical degree from the New York Medical College and completed a medical oncology fellowship at the US National Cancer Institute.
Also joining AstraZeneca, effective early September, is Jean-Charles Soria who becomes head of innovative oncology medicines at the company’s MedImmune unit. Dr Soria will be responsible for the early oncology portfolio. Prior to joining MedImmune, he was professor of medicine and medical oncology at South-Paris University in France.
AstraZeneca Plc announced the appointments on 31 July 2017.
Copyright 2017 Evernow Publishing Ltd